Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (April 2009)
15 slides from Somnomed's investor presentation, Apr 27, 2009
Slide 1: Investor Presentation April 2009
For personal use only “Improving Health and Quality of Life Through Better Breathing and Sleep ” Investor Presentation April 2009
Slide 2: SomnoMed company overview
For personal use only SomnoMed is a Sydney-based ASX-listed company (ASX code: SOM) which was formed in 2004 to commercialise its mandibular advancement splint (MAS), the SomnoDent® MAS. The SomnoDent® MAS is a patented, clinically proven, patient compliant medical device which is highly effective i
Slide 3: Vision and Mission
For personal use only Vision Improving Health and Quality of Life Through Better Breathing and Sleep Mission Global leadership in Dental Sleep Medicine offering evidence based, non- invasive, innovative solutions advancing the treatment of sleep-disordered breathing.
Slide 4: Background Sleep Disordered Breathing (SDB)
For personal use only Background Sleep Disordered Breathing (SDB) Obstructive Sleep Apnea (OSA) is a common disorder caused by repeated obstruction of the upper airway during sleep. The disorder is characterised by periods of breathing cessation (apnea) and reduced breathing (hypoapnea). OSA has bee
Slide 5: Traditional SDB Treatment Options
Traditional SDB Treatment Options For personal use only Surgery Irreversible Success rate 50% Painful, slow recovery Very expensive Success rate *100% CPAP Compliance 50% (Continuous Positive Airway Pressure) Expensive *Success rate defined as reduction of AHI (apnea hypopnea index) to less than 5 /
Slide 6: SomnoDent - Third Generation Treatment Option
SomnoDent® - Third Generation Treatment Option For personal use only SomnoDent® Success rate *50-70% Comfortable (Mandibular Advancement Splint) Compliance >90% Least expensive Patented – Clinically Proven – Compliant OSA Treatment *Success rate defined as reduction of AHI (apnea hypopnea index) to
Slide 7: Strong Growth Expected in SDB Treatment Market
Strong Growth Expected in SDB Treatment Market For personal use only CPAP > 2 Billion US$ Revenue in 2008 6,000,000 • 15 – 20% growth rate p.a. 5,000,000 • > 60% of diagnosed patients 20% are untreated 4,000,000 • Shift expected to a more compliant Oral Appliance Therapy # units 80% OAT 3,000,000 CP
Slide 8: SomnoMed's Growth Story
SomnoMed’s Growth Story For personal use only • 2004 - Listed on the Australian Stock Exchange (ASX: SOM) • 2005 - Start up and infrastructure development • 2006 – FDA approval, Expansion into US market • 2007 – Restructure, New Management, CE approval, Expansion into European and Asian market • 200
Slide 9: Strategic Objectives in FY 08/09
Strategic Objectives in FY 08/09 (ASX Sept 08) For personal use only • 2008/09 - Increase global sales worldwide by more than 100% to 14,000 devices; => total units sales of approx 11,000-12,000 devices expected in FY 08-09 - Sales revenue increase from A$ 3.6 million to over A$ 7 million - Profitab
Slide 10: North America Drives Volume Growth
North America Drives Volume Growth For personal use only Units sold per quarter Total 3000 2500 2000 North America Units 1500 1000 APAC 500 Europe 0 Sep-06 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Mar-08 Jun-08 Sep-08 Dec-08 Mar-09
Slide 11: Strong Growth in Revenue and Gross Margin
Strong Growth in Revenue and Gross Margin For personal use only $9,000 209% Growth in $8,000 Sales Revenue since 05/06 $7,000 $6,000 $5,518 $5,000 $A'000 $4,000 $3,658 $3,000 260% Growth in $2,273 Gross Margin $2,000 $1,786 since 05/06 $2,885 $1,000 $1,957 $801 $1,002 $0 FY 05/06 FY 06/07 FY 07/08 9
Slide 12: Operating Profitability Before Corporate Expenses
Operating Profitability Before Corporate Expenses Achieved in first 9 months of FY 08/09 For personal use only FY 05/06 FY 06/07 FY 07/08 9M TH 08/09 $500 $65 $0 -$500 -$1,000 -$934 $A'000 -$1,500 -$1,589 -$2,000 -$2,500 -$3,000 -$3,262 -$3,500
Slide 13: Q3 Operating Profit before Corporate Expenses
Q3 Operating Profit before Corporate Expenses For personal use only $ 204 $ -50 $ -89 Q1 Q2 Q3
Slide 14: Continued Growth expected for FY 09-10
Continued Growth expected for FY 09-10 For personal use only 20,000 18000-22000 18,000 16,000 14,000 #units 12,000 11000-12000 10,000 8,000 7000 6,000 3500 4,000 2500 1500 2,000 0 FY 04/05 FY 05/06 FY 06/07 FY 07/08 FY 08/09 FY 09/10 Source: Company data and estimates
Slide 15: SomnoMed Contacts
SomnoMed Contacts For personal use only Chairman Dr Peter Neustadt Chief Executive Officer Mr Ralf Barschow Address Level 3, 20 Clarke Street Crows Nest, NSW, 2065 Australia Telephone +61 (0)2 9467 0400 Website www.somnomed.com.au